Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALEC NASDAQ:ALVR NASDAQ:CCCC NASDAQ:REPL NASDAQ:RGNX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALECAlector$1.50+2.0%$2.77$0.87▼$6.14$148.78M0.994.06 million shs6.64 million shsALVRAlloVir$4.77-2.5%$4.55$7.96▼$24.15$24.06M0.6315,685 shs42,286 shsCCCCC4 Therapeutics$2.45+2.9%$2.55$1.09▼$6.52$169.39M2.942.80 million shs1.81 million shsREPLReplimune Group$8.80+4.5%$5.36$2.68▼$17.00$657.23M0.428.59 million shs2.19 million shsRGNXREGENXBIO$13.03+3.6%$10.06$5.03▼$13.39$635.47M1.17664,037 shs461,729 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALECAlector+2.04%-50.66%-52.53%-14.77%-67.88%ALVRAlloVir+11.64%+2.09%+2.52%+77.17%-72.10%CCCCC4 Therapeutics+2.94%+3.38%+1.24%+8.41%-59.44%REPLReplimune Group+4.51%+95.56%+111.54%+179.37%-26.73%RGNXREGENXBIO+3.58%+11.08%+36.58%+45.42%+33.78%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALECAlector$1.50+2.0%$2.77$0.87▼$6.14$148.78M0.994.06 million shs6.64 million shsALVRAlloVir$4.77-2.5%$4.55$7.96▼$24.15$24.06M0.6315,685 shs42,286 shsCCCCC4 Therapeutics$2.45+2.9%$2.55$1.09▼$6.52$169.39M2.942.80 million shs1.81 million shsREPLReplimune Group$8.80+4.5%$5.36$2.68▼$17.00$657.23M0.428.59 million shs2.19 million shsRGNXREGENXBIO$13.03+3.6%$10.06$5.03▼$13.39$635.47M1.17664,037 shs461,729 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALECAlector+2.04%-50.66%-52.53%-14.77%-67.88%ALVRAlloVir+11.64%+2.09%+2.52%+77.17%-72.10%CCCCC4 Therapeutics+2.94%+3.38%+1.24%+8.41%-59.44%REPLReplimune Group+4.51%+95.56%+111.54%+179.37%-26.73%RGNXREGENXBIO+3.58%+11.08%+36.58%+45.42%+33.78%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALECAlector 1.82Reduce$3.00100.00% UpsideALVRAlloVir 0.00N/AN/AN/ACCCCC4 Therapeutics 2.43Hold$8.50246.94% UpsideREPLReplimune Group 2.45Hold$11.0025.00% UpsideRGNXREGENXBIO 2.57Moderate Buy$28.38117.77% UpsideCurrent Analyst Ratings BreakdownLatest REPL, ALVR, RGNX, ALEC, and CCCC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/24/2025ALECAlectorWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/24/2025CCCCC4 TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/22/2025ALECAlectorHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$10.00 ➝ $5.0010/22/2025ALECAlectorWilliam BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform10/22/2025ALECAlectorCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Neutral10/22/2025ALECAlectorCowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold10/22/2025ALECAlectorMizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOutperform ➝ Neutral$1.5010/22/2025ALECAlectorMizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Neutral$1.5010/22/2025ALECAlectorBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral10/22/2025ALECAlectorTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold10/20/2025REPLReplimune GroupLeerink PartnrsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy(Data available from 10/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALECAlector$100.56M1.51N/AN/A$1.29 per share1.16ALVRAlloVirN/AN/AN/AN/A$29.35 per shareN/ACCCCC4 Therapeutics$35.58M4.90N/AN/A$3.06 per share0.80REPLReplimune GroupN/AN/AN/AN/A$5.40 per shareN/ARGNXREGENXBIO$155.78M4.23N/AN/A$5.24 per share2.49Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALECAlector-$119.05M-$1.16N/AN/AN/A-142.10%-112.06%-26.37%11/5/2025 (Estimated)ALVRAlloVir-$190.42M-$20.23N/A∞N/AN/A-71.03%-61.27%11/10/2025 (Estimated)CCCCC4 Therapeutics-$105.32M-$1.58N/AN/AN/A-325.88%-53.91%-33.26%10/30/2025 (Estimated)REPLReplimune Group-$247.30M-$3.24N/AN/AN/AN/A-69.34%-52.81%11/11/2025 (Estimated)RGNXREGENXBIO-$227.10M-$3.44N/AN/AN/A-112.70%-66.95%-34.14%11/5/2025 (Estimated)Latest REPL, ALVR, RGNX, ALEC, and CCCC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q2 2026REPLReplimune Group-$0.86N/AN/AN/A$0.50 millionN/A11/5/2025Q3 2025ALECAlector-$0.40N/AN/AN/A$3.49 millionN/A11/5/2025Q3 2025RGNXREGENXBIO-$1.38N/AN/AN/A$24.41 millionN/A10/30/2025Q3 2025CCCCC4 Therapeutics-$0.43N/AN/AN/AN/AN/A8/7/2025Q2 2025ALECAlector-$0.45-$0.30+$0.15-$0.30$2.76 million$7.87 million8/7/2025Q2 2025CCCCC4 Therapeutics-$0.38-$0.37+$0.01-$0.37$5.24 million$6.46 million8/7/2025Q1 2026REPLReplimune Group-$0.83-$0.95-$0.12-$0.95$0.50 millionN/A8/7/2025Q2 2025RGNXREGENXBIO-$1.13-$1.38-$0.25-$1.38$40.87 million$21.36 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALECAlectorN/AN/AN/AN/AN/AALVRAlloVirN/AN/AN/AN/AN/ACCCCC4 TherapeuticsN/AN/AN/AN/AN/AREPLReplimune GroupN/AN/AN/AN/AN/ARGNXREGENXBION/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALECAlector0.133.783.78ALVRAlloVirN/A86.7886.78CCCCC4 TherapeuticsN/A5.065.06REPLReplimune Group0.216.946.94RGNXREGENXBION/A3.133.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALECAlector85.83%ALVRAlloVir66.05%CCCCC4 Therapeutics78.81%REPLReplimune Group92.53%RGNXREGENXBIO88.08%Insider OwnershipCompanyInsider OwnershipALECAlector9.70%ALVRAlloVir32.07%CCCCC4 Therapeutics8.73%REPLReplimune Group5.20%RGNXREGENXBIO12.79%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALECAlector270101.21 million91.39 millionOptionableALVRAlloVir1105.04 million3.43 millionOptionableCCCCC4 Therapeutics15071.17 million64.96 millionOptionableREPLReplimune Group21078.06 million74.00 millionOptionableRGNXREGENXBIO37050.51 million44.05 millionOptionableREPL, ALVR, RGNX, ALEC, and CCCC HeadlinesRecent News About These CompaniesREGENXBIO (NASDAQ:RGNX) Reaches New 52-Week High - Here's WhyOctober 22 at 5:54 AM | marketbeat.comRaymond James Remains a Buy on RegenXBio (RGNX)October 21, 2025 | theglobeandmail.comGoldman Sachs Sticks to Its Hold Rating for RegenXBio (RGNX)October 19, 2025 | theglobeandmail.comRegenXBio (RGNX) Receives a Buy from Raymond JamesOctober 19, 2025 | theglobeandmail.comREGENXBIO (NASDAQ:RGNX) Shares Gap Down - What's Next?October 18, 2025 | marketbeat.comREGENXBIO (NASDAQ:RGNX) Reaches New 1-Year High - Still a Buy?October 17, 2025 | marketbeat.comREGENXBIO (NASDAQ:RGNX) Trading 8.5% Higher - Should You Buy?October 15, 2025 | marketbeat.comREGENXBIO to Participate in Upcoming Investor ConferencesOctober 15, 2025 | prnewswire.comAnalysts Offer Insights on Healthcare Companies: Anavex Life Sciences (AVXL), RegenXBio (RGNX) and Vera Therapeutics (VERA)October 14, 2025 | theglobeandmail.comREGENXBIO (NASDAQ:RGNX) CEO Curran Simpson Sells 20,811 SharesOctober 11, 2025 | marketbeat.comREGENXBIO (NASDAQ:RGNX) Stock Price Down 4.7% - What's Next?October 11, 2025 | marketbeat.comCurran Simpson Sells 20,811 Shares of REGENXBIO (NASDAQ:RGNX) StockOctober 11, 2025 | insidertrades.comREGENXBIO (NASDAQ:RGNX) Reaches New 12-Month High - Time to Buy?October 10, 2025 | marketbeat.comWeiss Ratings Reiterates "Sell (D-)" Rating for REGENXBIO (NASDAQ:RGNX)October 10, 2025 | marketbeat.comREGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual MeetingOctober 9, 2025 | prnewswire.comREGENXBIO (NASDAQ:RGNX) Trading 9.1% Higher - Should You Buy?October 8, 2025 | marketbeat.comREGENXBIO Inc. (NASDAQ:RGNX) Receives Average Rating of "Moderate Buy" from AnalystsOctober 8, 2025 | marketbeat.comThe Analyst Verdict: Regenxbio In The Eyes Of 7 ExpertsOctober 7, 2025 | benzinga.comHC Wainwright & Co. Reiterates REGENXBIO (RGNX) Buy RecommendationOctober 7, 2025 | msn.com7 Analysts Assess Regenxbio: What You Need To KnowOctober 7, 2025 | benzinga.comREGENXBIO's (RGNX) "Buy" Rating Reiterated at HC WainwrightOctober 7, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeREPL, ALVR, RGNX, ALEC, and CCCC Company DescriptionsAlector NASDAQ:ALEC$1.50 +0.03 (+2.04%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$1.48 -0.01 (-1.00%) As of 10/24/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.AlloVir NASDAQ:ALVR$4.77 -0.12 (-2.45%) As of 10/24/2025AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.C4 Therapeutics NASDAQ:CCCC$2.45 +0.07 (+2.94%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$2.48 +0.03 (+1.43%) As of 10/24/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Replimune Group NASDAQ:REPL$8.80 +0.38 (+4.51%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$8.66 -0.14 (-1.53%) As of 10/24/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.REGENXBIO NASDAQ:RGNX$13.03 +0.45 (+3.58%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$13.04 +0.02 (+0.12%) As of 10/24/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 10/20 - 10/24 Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Fal.Con Europe Could Be CrowdStrike’s Early Earnings Catalyst Logitech Eyes Breakout Before Earnings—Citigroup Sees 30% Upside Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Capital One Just Flashed a Buy Signal—New Highs Could Be Next Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
